Yangbo Feng, Ph.D.

Roles

• Biography

  + –
  Dr. Feng is a Research Associate Professor in the Department of Molecular and Cellular Pharmacology, and the Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. He is a medicinal chemist with extensive research experience in both academic and industry settings. Dr. Feng has been working on small molecule drug discovery and preclinical drug development over the past 35+ years. Dr. Feng has published more than 60 manuscripts in peer-reviewed journals and has filed 30 patent applications.

• Education & Training

  + –

  Education

  1996: University of California, San Diego, California

  PhD, Organic Chemistry

  1986: Beijing Institute of Chemistry, Academia Sinica, China

  MS, Chemistry

  1983: Wuhan University, Wuhan, China

  BS, Chemistry

  Post Graduate Training

  1999: Texas A&M University, Texas

  Post-Doctoral Fellowship, Medicinal Chemistry

• Research Interests

  + –
  Dr. Feng's research interests are in small molecule drug discovery (DD) and development. We apply a variety of strategies in preclinical drug discovery and development, such as the Target-Driven Drug Discovery, the Compound-Driven Strategy, the Fragment Based Drug Discovery, and the Structure Based Drug Discovery, etc.

• Publications

  + –
  Disclaimer: The information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, please use this link to inform our data team. Your feedback is greatly appreciated and helps us improve the quality of our content.

  
  

  See all Publications

• Copyrights & Patents

  + –

  ARGININE VASOPRESSIN RECEPTOR (AVPR) ANTAGONISTS AND METHODS OF USING THEREOF

  283204519936, Patent

  Bidentate-Binding Modulators of LRRK2 and JNK Kinases

  283210340352, Patent

  Compounds for proliferative disorders

  283204581376, Patent

  “Histone Deacetylase Inhibitors and Methods of Use Thereof”

  283210278912, Patent

  “JNK3-selective inhibitors for the treatment of neurodegenerative diseases”.

  283210096640, Patent

  “Novel JNK3 inhibitors for the treatment of neurodegenerative diseases”

  283210067968, Patent

  “Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof”

  283210190848, Patent

  Selective Modulators of JNK Isoforms 2 and 3

  283210387456, Patent

  “Selective Bromodomain inhibitors and methods for use thereof”

  283210121216, Patent